RS55307B1 - Derivati imidazolpiridazina kao modulatori receptora gabaa - Google Patents

Derivati imidazolpiridazina kao modulatori receptora gabaa

Info

Publication number
RS55307B1
RS55307B1 RS20160986A RSP20160986A RS55307B1 RS 55307 B1 RS55307 B1 RS 55307B1 RS 20160986 A RS20160986 A RS 20160986A RS P20160986 A RSP20160986 A RS P20160986A RS 55307 B1 RS55307 B1 RS 55307B1
Authority
RS
Serbia
Prior art keywords
receptor modulators
gabaa receptor
imidazopyridazine derivatives
imidazopyridazine
derivatives
Prior art date
Application number
RS20160986A
Other languages
English (en)
Inventor
Kiyoyuki Omoto
Robert Mckenzie Owen
David Cameron Pryde
Christine Anne Louise Watson
Mifune Takeuchi
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of RS55307B1 publication Critical patent/RS55307B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
RS20160986A 2012-12-14 2013-12-04 Derivati imidazolpiridazina kao modulatori receptora gabaa RS55307B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737157P 2012-12-14 2012-12-14
PCT/IB2013/060631 WO2014091368A1 (en) 2012-12-14 2013-12-04 Imidazopyridazine derivatives as gabaa receptor modulators

Publications (1)

Publication Number Publication Date
RS55307B1 true RS55307B1 (sr) 2017-03-31

Family

ID=49880883

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160986A RS55307B1 (sr) 2012-12-14 2013-12-04 Derivati imidazolpiridazina kao modulatori receptora gabaa

Country Status (44)

Country Link
US (3) US8952008B2 (sr)
EP (1) EP2938615B1 (sr)
JP (1) JP5869740B2 (sr)
KR (1) KR101746314B1 (sr)
CN (1) CN104837843B (sr)
AP (1) AP2015008526A0 (sr)
AR (1) AR093937A1 (sr)
AU (1) AU2013356894B2 (sr)
BR (1) BR112015014097B1 (sr)
CA (1) CA2892174C (sr)
CL (1) CL2015001652A1 (sr)
CR (1) CR20150254A (sr)
CU (1) CU24338B1 (sr)
CY (1) CY1118568T1 (sr)
DK (1) DK2938615T3 (sr)
DO (1) DOP2015000147A (sr)
EA (1) EA025635B1 (sr)
EC (1) ECSP15029822A (sr)
ES (1) ES2608640T3 (sr)
GE (1) GEP201706710B (sr)
GT (1) GT201500159A (sr)
HK (1) HK1209743A1 (sr)
HR (1) HRP20161559T1 (sr)
HU (1) HUE032400T2 (sr)
IL (1) IL239243A0 (sr)
LT (1) LT2938615T (sr)
MA (1) MA38112B1 (sr)
MD (1) MD4651B1 (sr)
ME (1) ME02566B (sr)
MX (1) MX366023B (sr)
NI (1) NI201500081A (sr)
PE (1) PE20151163A1 (sr)
PH (1) PH12015501293A1 (sr)
PL (1) PL2938615T3 (sr)
PT (1) PT2938615T (sr)
RS (1) RS55307B1 (sr)
SG (1) SG11201503735YA (sr)
SI (1) SI2938615T1 (sr)
TN (1) TN2015000261A1 (sr)
TW (1) TWI478926B (sr)
UA (1) UA112028C2 (sr)
UY (1) UY35185A (sr)
WO (1) WO2014091368A1 (sr)
ZA (1) ZA201504226B (sr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015189744A1 (en) * 2014-06-12 2015-12-17 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity.
PT3174858T (pt) 2014-07-31 2019-07-23 Basf Se Processo para preparar pirazoles
ES2882543T3 (es) 2015-05-11 2021-12-02 Basf Se Proceso para la preparación de 4-amino-piridazinas
EP3386983A1 (en) * 2015-12-10 2018-10-17 Pfizer Limited 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
WO2018055550A1 (en) * 2016-09-23 2018-03-29 Novartis Ag Indazole compounds for use in tendon and/or ligament injuries
JOP20190053A1 (ar) * 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
WO2018082964A1 (en) 2016-11-04 2018-05-11 Basf Se Process for the production of pyridazinyl-amides in a one-pot synthesis
WO2018202494A1 (de) 2017-05-02 2018-11-08 Bayer Aktiengesellschaft 2-(het)aryl-substituierte kondensierte heterocyclen-derivate als schädlingsbekämpfungsmittel
EP3634420A1 (en) * 2017-06-06 2020-04-15 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
WO2019226820A1 (en) * 2018-05-22 2019-11-28 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds for treatment of itch and/ or dermatitis
TW202214648A (zh) * 2019-01-07 2022-04-16 美商美國禮來大藥廠 Il-17a抑制劑
CN116693555A (zh) * 2022-02-25 2023-09-05 上海赛默罗生物科技有限公司 咪唑并哒嗪类衍生物、其制备方法、药物组合物和用途
CN117069725A (zh) * 2022-05-10 2023-11-17 上海赛默罗生物科技有限公司 咪唑并哒嗪取代苯环类衍生物、制备方法、药物组合物及用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
ES2251518T3 (es) 2000-11-10 2006-05-01 MERCK SHARP & DOHME LTD. Derivados de imidazo-triazina como ligandos para receptores gaba.
GB0117277D0 (en) 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
CA2555263A1 (en) * 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
US20080132510A1 (en) 2005-01-21 2008-06-05 Bingsong Han Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
EP1995241B1 (en) 2007-03-23 2010-03-17 ICAgen, Inc. Inhibitors of ion channels
MA32965B1 (fr) 2009-01-12 2012-01-02 Pfizer Ltd Derives de sulfonamides
MX2012004990A (es) * 2009-10-30 2012-06-12 Janssen Pharmaceutica Nv Deribados de imidazo [1,2-b] pirimideazina y su uso como inhibidores de la enzima fosfodiesterasa 10.
ES2526675T3 (es) * 2010-07-09 2015-01-14 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje

Also Published As

Publication number Publication date
HUE032400T2 (hu) 2017-09-28
TN2015000261A1 (fr) 2016-10-03
ES2608640T3 (es) 2017-04-12
CU24338B1 (es) 2018-04-03
AP2015008526A0 (en) 2015-06-30
TWI478926B (zh) 2015-04-01
AU2013356894B2 (en) 2015-11-12
IL239243A0 (en) 2015-07-30
EP2938615B1 (en) 2016-10-26
AU2013356894A1 (en) 2015-05-28
EP2938615A1 (en) 2015-11-04
DOP2015000147A (es) 2015-09-15
UY35185A (es) 2014-07-31
AR093937A1 (es) 2015-07-01
NI201500081A (es) 2015-09-16
ME02566B (me) 2017-02-20
CA2892174A1 (en) 2014-06-19
PT2938615T (pt) 2016-12-26
DK2938615T3 (da) 2017-01-02
MA38112B1 (fr) 2018-10-31
SG11201503735YA (en) 2015-07-30
CA2892174C (en) 2018-02-06
KR101746314B1 (ko) 2017-06-12
MX366023B (es) 2019-06-24
GT201500159A (es) 2015-09-23
MD20150051A2 (ro) 2015-09-30
SI2938615T1 (sl) 2017-02-28
PL2938615T3 (pl) 2017-04-28
ECSP15029822A (es) 2017-08-31
CN104837843A (zh) 2015-08-12
PH12015501293B1 (en) 2015-08-24
US20150259352A1 (en) 2015-09-17
JP5869740B2 (ja) 2016-02-24
CL2015001652A1 (es) 2015-08-14
PE20151163A1 (es) 2015-08-14
US8952008B2 (en) 2015-02-10
US20140171435A1 (en) 2014-06-19
CR20150254A (es) 2015-07-09
HK1209743A1 (zh) 2016-04-08
BR112015014097A2 (pt) 2019-12-17
HRP20161559T1 (hr) 2016-12-30
EA201590761A1 (ru) 2015-12-30
MX2015007598A (es) 2015-10-22
WO2014091368A1 (en) 2014-06-19
LT2938615T (lt) 2016-12-27
CU20150058A7 (es) 2015-11-27
PH12015501293A1 (en) 2015-08-24
CN104837843B (zh) 2016-08-31
GEP201706710B (en) 2017-07-25
ZA201504226B (en) 2016-06-29
MA38112A1 (fr) 2018-03-30
BR112015014097B1 (pt) 2022-11-29
JP2016503001A (ja) 2016-02-01
TW201434840A (zh) 2014-09-16
UA112028C2 (uk) 2016-07-11
US20150105396A1 (en) 2015-04-16
MD4651B1 (ro) 2019-09-30
CY1118568T1 (el) 2017-07-12
KR20150088877A (ko) 2015-08-03
EA025635B1 (ru) 2017-01-30

Similar Documents

Publication Publication Date Title
HK1209743A1 (zh) 作為 受體調節劑的咪唑並噠嗪衍生物
IL237126A (en) Derivatives in cicadas
GB201213700D0 (en) Receptor antagnists II
PL2663550T4 (pl) Podstawione benzoazepiny jako modulatory receptora toll-podobnego
PL2663555T4 (pl) Podstawione benzoazepiny jako modulatory receptora toll-podobnego
IL232112A0 (en) Transduced imidazopyrimidines as modulators of 1gpbar receptors
IL251897A0 (en) X-receptor modulators of the liver
HK1206333A1 (en) Liver receptor modulators
IL235557B (en) Modulators of 17 gpr receptors
PT3345899T (pt) Derivados de benzofurano-2-sulfonamida como moduladores dos receptores de quimioquinas
GB201223053D0 (en) Receptor
GB2501462B (en) Structural fixing
AU5018P (en) Dark Star Tulbaghia hybrid
GB201202526D0 (en) Structural fixing
HUP1200360A2 (en) Resolution by using n-acyl-phenylglycine derivatives